3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Mesothelioma, Malignant
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Paclitaxel
3
Ipilimumab
3
Cyclophosphamide
3
Carboplatin
3
padeliporfin
2
atezolizumab
2
anlotinib
2
Riluzole
2
Gemcitabine
2
vinflunine
1
sipuleucel-T
1
relatlimab
1
palbociclib
1
olaparib
1
niraparib
1
motexafin gadolinium
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
cabozantinib
1
Therapeutics
1
Suspensions
1
Surveys and Questionnaires
1
Sunitinib
1
Specimen Handling
1
Powders
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urogenital Neoplasms
×
niraparib
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled